XJPX4556
Market cap33mUSD
Jan 17, Last price
1,269.00JPY
1D
-0.31%
1Q
6.73%
Jan 2017
106.34%
Name
Kainos Laboratories Inc
Chart & Performance
P/E
8.30
P/S
1.05
EPS
152.84
Div Yield, %
2.10%
Shrs. gr., 5y
—
Rev. gr., 5y
-2.83%
Revenues
5.06b
+2.71%
Net income
638m
+12.28%
CFO
431m
-20.92%
Dividend
Mar 28, 20250 JPY/sh
Profile
KAINOS Laboratories, Inc. engages in the development, manufacture, marketing, distribution, and import/export of pharmaceuticals, diagnostic reagents, and related chemical products in Japan. It is also involved in the development, manufacture, marketing, distribution, and import/export of physical and chemical measurement instruments, and medical supplies, as well as nutrition supplements, foodstuff, animal feed, and related products. The company offers various biochemical clinical testing reagents systems, such as Aqua-auto Kainos CRE-IV Test Kit, a liquid form creatinine measurement reagent kit for various makes of automatic analyzer systems; Aqua-auto Kainos ALB Test Kit, a liquid form reagent kit; and Aqua-auto Kainos UN-II Test Kit, a liquid urea nitrogen measurement reagent kit. In addition, it provides FGF-23 ELISA Kit, a two-site enzyme-linked immunosorbent assay kit for the measurement of FGF-23 in serum. Further, the company offers point of care testing solutions comprising Swiftgene Norovirus GI/GII Kainos for detecting noroviruses; Statmark FLUstick II for detecting type A and type B influenza virus antigens; and Statmark Strep A for detecting Group A beta-hemolytic streptococci. The company was formerly known as DOMS-IATRON Co., Ltd. and changed its name to KAINOS Laboratories, Inc. in July 1975. KAINOS Laboratories, Inc. was founded in 1975 and is headquartered in Tokyo, Japan.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | |
| Income | |||||
Revenues | 5,056,463 2.71% | 4,923,245 6.69% | 4,614,725 8.38% | ||
Cost of revenue | 3,038,647 | 2,935,344 | 2,694,275 | ||
Unusual Expense (Income) | |||||
NOPBT | 2,017,816 | 1,987,901 | 1,920,450 | ||
NOPBT Margin | 39.91% | 40.38% | 41.62% | ||
Operating Taxes | 292,104 | 276,991 | 254,790 | ||
Tax Rate | 14.48% | 13.93% | 13.27% | ||
NOPAT | 1,725,712 | 1,710,910 | 1,665,660 | ||
Net income | 637,965 12.28% | 568,174 10.90% | 512,334 22.74% | ||
Dividends | (111,173) | (111,736) | (65,679) | ||
Dividend yield | 2.19% | 2.57% | 1.61% | ||
Proceeds from repurchase of equity | (50) | 92,370 | |||
BB yield | 0.00% | -2.27% | |||
| Debt | |||||
Debt current | 563,958 | 480,389 | 412,170 | ||
Long-term debt | 371,976 | 561,803 | 603,042 | ||
Deferred revenue | |||||
Other long-term liabilities | 45,266 | 69,210 | 54,820 | ||
Net debt | (2,456,731) | (2,164,485) | (1,834,596) | ||
| Cash flow | |||||
Cash from operating activities | 430,578 | 544,510 | 604,363 | ||
CAPEX | (75,707) | (7,696) | (141,170) | ||
Cash from investing activities | (72,828) | (10,328) | (141,187) | ||
Cash from financing activities | (203,726) | (191,136) | (31,255) | ||
FCF | 1,223,954 | 1,579,723 | 1,575,456 | ||
| Balance | |||||
Cash | 3,173,883 | 3,019,848 | 2,676,787 | ||
Long term investments | 218,782 | 186,829 | 173,021 | ||
Excess cash | 3,139,842 | 2,960,515 | 2,619,072 | ||
Stockholders' equity | 5,219,919 | 5,191,627 | 4,722,102 | ||
Invested Capital | 4,034,676 | 3,502,061 | 3,370,915 | ||
ROIC | 45.79% | 49.79% | 49.75% | ||
ROCE | 28.12% | 30.76% | 32.06% | ||
| EV | |||||
Common stock shares outstanding | 4,190 | 4,174 | 4,054 | ||
Price | 1,209.00 16.14% | 1,041.00 3.58% | 1,005.00 -1.57% | ||
Market cap | 5,065,783 16.59% | 4,345,051 6.65% | 4,073,973 -3.80% | ||
EV | 2,609,052 | 2,180,566 | 2,239,377 | ||
EBITDA | 2,136,538 | 2,129,428 | 2,070,598 | ||
EV/EBITDA | 1.22 | 1.02 | 1.08 | ||
Interest | 6,988 | 7,565 | 7,594 | ||
Interest/NOPBT | 0.35% | 0.38% | 0.40% | ||